PNPLA3 and metabolic dysfunction-associated steatotic liver disease: These studies are critical because they will serve to both further validate that in vitro MPS platforms recapitulate actual clinical patient data and evaluate whether differences in the production of specific cytokines can be used as potential biomarkers for stratifying MASLD patients with or without the PNPLA3 polymorphism.